{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:07:31Z","timestamp":1779808051634,"version":"3.53.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejogrb.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T08:04:19Z","timestamp":1482480259000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial"],"prefix":"10.1016","volume":"210","author":[{"given":"M.","family":"Sayyah-Melli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mobasseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Gharabaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ouladsahebmadarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2016.11.001_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/IJWH.S51083","article-title":"Uterine fibroids: current perspectives","volume":"6","author":"Khan","year":"2014","journal-title":"Int J Womens Health"},{"issue":"Suppl. 3","key":"10.1016\/j.ejogrb.2016.11.001_bib0010","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.4103\/2141-9248.141955","article-title":"Pharmacological treatment of uterine fibroids","volume":"4","author":"Moroni","year":"2014","journal-title":"Ann Med Health Sci Res"},{"issue":"2","key":"10.1016\/j.ejogrb.2016.11.001_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The management of uterine leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bpobgyn.2008.03.001","article-title":"Medical management of fibroids","volume":"22","author":"Sankaran","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0025","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3346\/jkms.2016.31.8.1279","article-title":"Effects of high-intensity-focused ultrasound treatment on benign uterine tumor","volume":"31","author":"Park","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0030","first-page":"364","article-title":"Alternatives to surgery for the treatment of myomas","volume":"68","author":"Ciolina","year":"2016","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0035","first-page":"553","article-title":"Carbone IF: GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review","volume":"58","author":"De Falco","year":"2006","journal-title":"Minerva Ginecol"},{"issue":"9","key":"10.1016\/j.ejogrb.2016.11.001_bib0040","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/humrep\/12.9.2028","article-title":"Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix","volume":"12","author":"Gonzalez-Barcena","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.15537\/1658-3175.3827","article-title":"Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and cabergoline (Dostinex) treatment on uterine myoma regression","volume":"28","author":"Melli","year":"2007","journal-title":"Saudi Med J"},{"issue":"8","key":"10.1016\/j.ejogrb.2016.11.001_bib0050","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.15537\/1658-3175.4796","article-title":"Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes","volume":"30","author":"Sayyah-Melli","year":"2009","journal-title":"Saudi Med J"},{"issue":"1","key":"10.1016\/j.ejogrb.2016.11.001_bib0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.fertnstert.2008.09.064","article-title":"A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozolee) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status","volume":"93","author":"Parsanezhad","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejogrb.2013.09.010","article-title":"Role of the aromatase inhibitor letrozolee in the management of uterine leiomyomas in premenopausal women","volume":"171","author":"Duhan","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"10.1016\/j.ejogrb.2016.11.001_bib0065","first-page":"1154","article-title":"Low dose mifepristone in medical management of uterine leiomyoma\u2014an experience from a tertiary care hospital from north India","volume":"137","author":"Kulshrestha","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0976-7800.109630","article-title":"Effect of mifepristone (25mg) in treatment of uterine myoma in perimenopausal woman","volume":"4","author":"Seth","year":"2013","journal-title":"J Mid-life Health"},{"issue":"3","key":"10.1016\/j.ejogrb.2016.11.001_bib0075","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7150\/ijms.7627","article-title":"Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro","volume":"11","author":"Chung","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/er.2005-0001","article-title":"Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis","volume":"26","author":"Chwalisz","year":"2005","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.ejogrb.2016.11.001_bib0085","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/humrep\/deh296","article-title":"Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas","volume":"19","author":"Palomba","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijgo.2011.07.031","article-title":"Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma","volume":"116","author":"Kriplani","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0095","first-page":"CD007692","article-title":"Danazol for uterine fibroids","volume":"3","author":"Ke","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ejogrb.2016.11.001_bib0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.biopha.2012.02.003","article-title":"Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ER\u03b1, Src and P38 MAPK","volume":"66","author":"Zhu","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1095\/biolreprod.111.098145","article-title":"1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model","volume":"86","author":"Halder","year":"2012","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0110","first-page":"CD008994","article-title":"Mol BW: Progestogens or progestogen-releasing intrauterine systems for uterine fibroids","volume":"2","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database Sys Rev"},{"issue":"3","key":"10.1016\/j.ejogrb.2016.11.001_bib0115","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/BF02864786","article-title":"Medicinal plants used by latino healers for women\u2019s health conditions in New York City","volume":"54","author":"Balick","year":"2000","journal-title":"Econom Bot"},{"issue":"Suppl. 2","key":"10.1016\/j.ejogrb.2016.11.001_bib0120","first-page":"15","article-title":"Anti-tumor effects of letrozole","volume":"20","author":"Miller","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1472-6483(10)60246-5","article-title":"Treatment of symptomatic uterine leiomyoma with letrozolee","volume":"17","author":"Gurates","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2014.07.040","article-title":"Preoperative treatment with letrozolee in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study","volume":"181","author":"Leone Roberti Maggiore","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0135","first-page":"CD009505","article-title":"Aromatase inhibitors for uterine fibroids","volume":"10","author":"Song","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2007.11.006","article-title":"Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients","volume":"91","author":"Hilario","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0145","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0015-0282(02)04761-1","article-title":"Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor","volume":"79","author":"Shozu","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.AOG.0000279151.20878.60","article-title":"The effect of anastrazole on symptomatic uterine leiomyomata","volume":"110","author":"Varelas","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0155","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.fertnstert.2010.01.072","article-title":"Letrozolee monotherapy in the treatment of uterine myomas","volume":"93","author":"Ferrero","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0160","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jgyn.2011.09.022","article-title":"Role of medical treatment for symptomatic leiomyoma management in premenopausal women","volume":"40","author":"Koskas","year":"2011","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0165","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.lpm.2013.02.318","article-title":"Medical treatment of symptomatic uterine leiomyomata in premenopausal woman","volume":"42","author":"Koskas","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jmig.2011.02.010","article-title":"Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Chen","year":"2011","journal-title":"J Minim Invas Gynecol"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0175","first-page":"CD000547","article-title":"Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids","volume":"2","author":"Lethaby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.fertnstert.2015.09.006","article-title":"Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones","volume":"105","author":"Malik","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0185","first-page":"CD010854","article-title":"Add-back therapy with GnRH analogues for uterine fibroids","volume":"20","author":"Moroni","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0190","first-page":"324","article-title":"Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women","volume":"77","author":"Iveson","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1600-0412.2012.01350.x","article-title":"Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial","volume":"91","author":"Badawy","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejogrb.2015.06.018","article-title":"Three-month treatment with triptorelin, letrozolee and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study","volume":"192","author":"Bizzarri","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0205","article-title":"Effectiveness of dopamine agonist, cabergoline (Dostinex) treatment on uterine myoma regression in comparison to the effect of gonadotrophin releasing hormone analog (GnRHa) Goserelin (Zoladex)","volume":"S33","author":"Elbareg","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0210","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0215","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-13-0099","article-title":"Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved","volume":"20","author":"L\u00f8nning","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejogrb.2016.11.001_bib0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-007-9704-7","article-title":"Safety of aromatase inhibitors in the adjuvant setting","volume":"105","author":"Perez","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejogrb.2016.11.001_bib0225","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1200\/jco.2005.23.16_suppl.533","article-title":"On behalf of the Z-FAST Trial: zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial","volume":"23","author":"Brufsky","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516310132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516310132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:00:12Z","timestamp":1779807612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211516310132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":45,"alternative-id":["S0301211516310132"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.11.001","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}